Selected article for: "acute respiratory syndrome and ARDS severity"

Author: Kariyanna, Pramod Theetha; Aurora, Lyudmila; Jayarangaiah, Apoorva; Yadav, Vivek; Hossain, Naseem. A.; Akter, Nasrin; Salifu, Moro O.; McFarlane, Isabel M.
Title: Utility of D-dimer as a Prognostic Factor in SARS CoV2 Infection: A Review
  • Cord-id: bx3svdrk
  • Document date: 2020_6_22
  • ID: bx3svdrk
    Snippet: Coronavirus Disease-2019 (COVID-19) is currently a public health emergency and has been listed by the World Health Organization (WHO) as a pandemic. It has commonly been associated with pulmonary manifestations and there is a growing body of evidence of multisystem involvement of the virus. As evidenced by various case reports and cohort studies, COVID-19-associated coagulopathy has been a common manifestation amongst the critically ill and has been associated with increased mortality. The prese
    Document: Coronavirus Disease-2019 (COVID-19) is currently a public health emergency and has been listed by the World Health Organization (WHO) as a pandemic. It has commonly been associated with pulmonary manifestations and there is a growing body of evidence of multisystem involvement of the virus. As evidenced by various case reports and cohort studies, COVID-19-associated coagulopathy has been a common manifestation amongst the critically ill and has been associated with increased mortality. The presence of venous thromboembolic events in patients who are critically ill due to COVID-19 has prompted the adoption of anticoagulation regimens aimed at preventing thromboembolic phenomena. Coagulation abnormalities have also been implicated in the progression and the severity of COVID-19 related acute respiratory distress syndrome (ARDS) and disseminated intravascular coagulation (DIC). There is strong evidence that D-dimer levels help predict which patients are at risk of thromboembolic events, progression to ARDS, DIC, immune dysregulation and mortality. We will review the utility of D-dimer as screening tool and in the risk stratification of COVID-19 patients prone to developing thromboembolic events, DIC, immune dysregulation and death. To date, the studies that have been published show the presence of elevated D-dimer levels in both the adult and pediatric populations and the measured level correlates with disease severity. Studies have also shown the relative increase of D-dimer levels in non-survivors compared to survivors. The elevation of D-dimer levels has shown to guide clinical decision making, namely the initiation of therapeutic anticoagulation and mortality benefit in patients with severe COVID-19 pneumonia compared to severe non COVID-19 pneumonia. Although the current body of literature suggested the use of D-dimer as a risk stratification tool and as a test to augment clinical judgement regarding the initiation of anticoagulation, randomized control trials are needed to fully understand the relationship between COVID-19 infection and the efficacy of D-dimer assays in clinical decision making.

    Search related documents:
    Co phrase search for related documents
    • acute ards respiratory distress syndrome and admission level: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
    • acute ards respiratory distress syndrome and lmwh weight heparin: 1, 2, 3, 4, 5, 6, 7
    • acute ards respiratory distress syndrome and low mortality: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24
    • adjunctive treatment and lmwh adjunctive treatment: 1
    • adjunctive treatment and lmwh weight heparin: 1
    • admission level and lmwh weight heparin: 1
    • admission level and low mortality: 1, 2, 3, 4, 5, 6
    • lmwh weight heparin and low mortality: 1, 2, 3, 4
    • lmwh weight heparin and macrovascular microvascular: 1